CV Sciences Inc (CVSI)

[BadKarmaKyle]

It took ZYNEX a year to get uplisted to NASDAQ. They just got approved yesterday. They had the same issues like we do. If you look at their 1 year stock chart it looks almost identical to us. NASDAQ works in mysterious ways I guess. But the good news is our financials are wayyy stronger than ZYNEX.

The bad news for CVSI in trying to make a comparison to Zynex, symbol ZYXI begins with ZYXI has been a company since 1996, 23 years and a public company since 2001,18 years. A long history of “clean hands.” Their issue for the delayed time frame is they continually had difficulty meeting the financial requirements. They don’t have the issues of the SEC “clean hands” doctrine. There are no Michael Mona’s with 20 million dollar judgments, multiple fraud lawsuits and SEC Fraud disciplinary actions, No Phytosphere valued at $35 million which the SEC determined was fraud. The SEC enforcement action against Mona and CVSI stated Mona knew all along how much the acquisition of Phytosphere was worth and reported a false figure on his company's financial reports as a means to manipulate its share price.

Separately, In 2011, Mona was on trial in California for a different fraud. There is so much fraud around this man and CVSI it’s difficult to keep track. After the trial, the court said he “intentionally defrauded” the plaintiff by “misrepresent[ing] material facts and conceal[ing] other material facts.” Mona was ordered to pay $16,886,132.16 for damages caused by his fraud. That figure is now $18,000,000.00 +/- and growing by over $12,000.00 per day.

(Source: Far West Indus. v. Mona, et al., California Superior Court, Riverside County, No. RIC495966.)"

“Unclean hands,” proven, fined and enforcement action taken by the SEC less then 2 years ago.

At ZYXI there have been no fines and nobody at ZYXI ever had to resign their position agreeing to not be an officer or have any job with a public company. Not for a day and particularly not for five years. No Bankruptcies, No State Tax Liens, No Federal Tax Liens at ZYXI., Their problem was and is they only have a 131.5 million dollar market cap but they have a far lower float then CVSI, only 33 million outstanding shares, 1/3 the float of CVSI. They also have a very low P/E Ratio,13.1 vs CVSI’s 74.43 or 6x lower. ZYXI earns $.2990 per share, CVSI earns $.066 per share or 20% of ZYXI. Saying CVSI has “waaaay better financials” just is not true. That’s why citations are imperative when you make such claims.They’re also not in a “grey “ area of the market with FDA Issues, Anti-Trust Issues but most importantly no stinky pinky issues.

ZYXI manufactures, designs and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. heir products are FDA Approved. Insurance Companies pay for their treatments when prescribed by a Dr. No Dr. prescribes PlusCBD except weed docs and they recommend it, not prescribe it. ZMS is a subsidiary of ZYXI and is in the process of developing its blood volume monitoring product. ZEU another subsidiary, this one overseas intends to focus on sales and marketing its products within the international marketplace upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products.

It’s products include NexWave, NeuroMove, InWave, Electrodes and Batteries. These are similar but upgraded modern TENS Units for a crib note explanation. ZMI devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation (TENS). All its medical devices are designed for home use. The ZMI devices are small, portable, battery operated and include an electrical pulse generator, which is connected to the body through electrodes. ZMI's primary product is the NexWave device, which is marketed to physicians and therapists by its field sales representatives. The NexWave requires consumable supplies, such as electrodes and batteries, which are shipped to patients on a recurring monthly basis, as needed. The NeuroMove contains electromyography and electric stimulation technology that is primarily used for stroke, spinal cord and traumatic brain injury rehabilitation (SCI), by reaching parts of the brain to re-connect with muscles, also known as neuroplasticity. The NeuroMove product is primarily marketed to medical clinics. InWave is used for electrical stimulation for treatment of female urinary incontinence.

ZMS develops and markets medical devices for non-invasive cardiac monitoring. The blood volume monitor is a non-invasive medical device for monitoring central blood volume that would be used in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. This device has been subjected to multiple clinical studies, which are being utilized for collecting data to further validate the algorithm used to determine changes in central blood volume and planning for future, additional clinical studies. The blood volume monitor has been tested in several International Review Board (IRB) approved studies and also used in several blood donation settings. It is in the process of building a number of commercial devices in pilot-production.


Here’s your citation,








I’ll be back later in the day with more detailed due diligence with more citations of the facts. Not conjecture, opinion or untruths.